A large randomised controlled intervention trial to prevent gastric cancer by eradication of Helicobacter pylori in Linqu County, China: Baseline results and factors affecting the eradication

Gut

Volumn 65, Issue 1, 2016, Pages 9-18

  Pan, Kai Feng ^a   Zhang, Lian ^a   Gerhard, Markus ^b   Ma, Jun Ling ^a   Liu, Wei Dong ^c   Ulm, Kurt ^b   Wang, Jian Xi ^c   Zhang, Lei ^a   Zhang, Yang ^a   Bajbouj, Monther ^b   Zhang, Lan Fu ^c   Li, Ming ^c   Vieth, Michael ^d   Liu, Rui Yong ^c   Quante, Michael ^b   Wang, Le Hua ^c   Suchanek, Stepan ^e   Zhou, Tong ^a   Guan, Wei Xiang ^a   Schmid, Roland ^b   Classen, Meinhard ^b,f   You, Wei Cheng ^a   more..

^a PEKING UNIVERSITY CANCER HOSPITAL AND INSTITUTE   (China)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c Healthy Bureau of Linqu County   (China)

^d INSTITUTE OF PATHOLOGY   (Germany)

^e CHARLES UNIVERSITY   (Czech Republic)

^f International Digestive Cancer Alliance   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BISMUTH CITRATE; METRONIDAZOLE; OMEPRAZOLE; PLACEBO; TETRACYCLINE; ANTIINFECTIVE AGENT; ANTIULCER AGENT;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ADULT; ANAMNESIS; ARTICLE; BACTERIAL CLEARANCE; BODY MASS; BREATH ANALYSIS; CANCER INCIDENCE; CANCER PREVENTION; CHINA; CONTROLLED STUDY; DIARRHEA; DISEASE ERADICATION; DIZZINESS; EDEMA; FEMALE; FOLLOW UP; HEADACHE; HELICOBACTER INFECTION; HUMAN; INTERVENTION STUDY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NAUSEA; PHYSICAL EXAMINATION; PREVALENCE; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; SEX DIFFERENCE; SINGLE DRUG DOSE; STOMACH CANCER; STRUCTURED QUESTIONNAIRE; UREA BREATH TEST; VOMITING; COMBINATION DRUG THERAPY; COMPLICATION; DOUBLE BLIND PROCEDURE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; MICROBIOLOGY; PROSPECTIVE STUDY; STOMACH NEOPLASMS; TREATMENT OUTCOME;

ADULT; ANTI-BACTERIAL AGENTS; ANTI-ULCER AGENTS; CHINA; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; METRONIDAZOLE; MIDDLE AGED; PROSPECTIVE STUDIES; STOMACH NEOPLASMS; TETRACYCLINE; TREATMENT OUTCOME;

EID: 84955579268     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2015-309197     Document Type: Article

References (48)

1. Huang JQ, Sridhar S, Hunt RH. Role of Helicobacter pylori infection and non-steroidal antiinflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet 2002;359:14-22.
2. Helicobacter and Cancer Collaborative Group. Gastric cancer and Helicobacter pylori: a combined analysis of 12 case control studies nested within prospective cohorts. Gut 2001;49:347-53.
3. Correa P, Miller MJ. Carcinogenesis, apoptosis and cell proliferation. Br Med Bull 1998;54:151-62.
4. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature 2014;513:202-9.
5. Correa P. Human gastric carcinogenesis: a multistep and multifactorial process-First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res 1992;52:6735-40.
6. [No authors listed]. Schistosomes, liver flukes and Helicobacter pylori. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Lyon, 7-14 June 1994. IARC Monogr Eval Carcinog Risks Hum 1994;61:1-241.
7. Malfertheiner P, Sipponen P, Naumann M, et al. Helicobacter pylori eradication has the potential to prevent gastric cancer: a state-of-the-art critique. Am J Gastroenterol 2005;100:2100-15.
8. You WC, Blot WJ, Li JY, et al. Precancerous gastric lesions in a population at high risk of stomach cancer. Cancer Res 1993;53:1317-21.
9. You WC, Zhang L, Pan KF, et al. Helicobacter pylori Prevalence and CagA status among children in two counties of China with high and low risks of gastric cancer. Ann Epidemiol 2001;11:543-6.
10. Zhang L, Blot WJ, You WC, et al. Helicobacter pylori antibodies in relation to precancerous gastric lesions in a high-risk Chinese population. Cancer Epidemiol Biomarkers Prev 1996;5:627-30.
11. You WC, Zhang L, Gail MH, et al. Gastric dysplasia and gastric cancer: Helicobacter pylori, serum vitamin C, and other risk factors. J Natl Cancer Inst 2000;92:1607-12.
12. You WC, Brown LM, Zhang L, et al. Randomized double-blind factorial trial of three treatments to reduce the prevalence of precancerous gastric lesions. J Natl Cancer Inst 2006;98:974-83.
13. Gail MH, You WC, Chang YS, et al. Factorial trial of three interventions to reduce the progression of precancerous gastric lesions in Shandong, China: design issues and initial data. Control Clin Trials 1998;19:352-69.
14. Ma JL, Zhang L, Brown LM, et al. Fifteen-year effects of Helicobacter pylori, garlic, and vitamin treatments on gastric cancer incidence and mortality. J Natl Cancer Inst 2012;104:488-92.
15. Li WQ, Ma JL, Zhang L, et al. Effects of Helicobacter pylori treatment on gastric cancer incidence and mortality in subgroups. J Natl Cancer Inst 2014;106. pii: dju116.
16. Ford AC, Forman D, Hunt RH, et al. Helicobacter pylori eradication therapy to prevent gastric cancer in healthy asymptomatic infected individuals: systematic review and meta-analysis of randomized controlled trials. BMJ 2014;348:g3174.
17. Helicobacter pylori eradication as a strategy for preventing gastric cancer. IARC working group reports. Volume 8. http://www.iarc.fr/en/publications/pdfs-online/wrk/wrk8/index.php
18. He J, Chen WQ. Chinese cancer registry annual report 2012. National Cancer Center, Disease Prevention and Control Bureau, Ministry of Health. 2012.
19. Wong BC, Zhang L, Ma JL, et al. Effects of selective COX-2 inhibitor and Helicobacter pylori eradication on precancerous gastric lesions. Gut 2012;61:812-18.
20. Zhang L, Shen L, Ma JL, et al. Eradication of H pylori infection in a rural population: one-day quadruple therapy versus 7-day triple therapy. World J Gastroenterol 2006;12:3915-18.
21. O'Morain C, Borody T, Farley A, et al. Efficacy and safety of single-triple capsules of bismuth biskalcitrate, metronidazole and tetracycline, given with omeprazole, for the eradication of Helicobacter pylori: an international multicentre study. Aliment Pharmacol Ther 2003;17:415-20.
22. Laine L, Hunt R, El-Zimaity H, et al. Bismuthbased quadruple therapy using a single capsule of bismuth biskalcitrate, metronidazole, and tetracycline given with omeprazole versus omeprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a prospective, randomized, multicenter, North American trial. Am J Gastroenterol 2003;98:562-7.
23. Zheng Q, Dai J, Li X, et al. Comparison of the efficacy of pantoprazole-based triple therapy versus quadruple therapy in the treatment of Helicobacter pylori infection. Chines J Gastroenterol 2009;14:38-40.
24. Ma J, Liu W, Zhang L, et al. A placebo-controlled trial of 10-day bismuth-based quadruple therapy to eradicate Helicobacter pylori infection; a pilot study for the large Linqu County trial. Eur J Gastroenterol Hepatol 2010;22:597-601.
25. Song Z, Zhang J, He L, et al. Prospective multi-region study on primary antibiotic resistance of Helicobacter pylori strains isolated from Chinese patients. Dig Liver Dis 2014;46:1077-81.
26. De Francesco V, Giorgio F, Hassan C, et al. Worldwide H. pylori antibiotic resistance: a systematic review. J Gastrointestin Liver Dis 2010;19:409-14.
27. El-Nakeeb A, Fikry A, Abd El-Hamed TM, et al. Effect of Helicobacter pylori eradication on ulcer recurrence after simple closure of perforated duodenal ulcer. Int J Surg 2009;7:126-9.
28. Ng EK, Lam YH, Sung JJ, et al. Eradication of Helicobacter pylori prevents recurrence of ulcer after simple closure of duodenal ulcer perforation: randomized controlled trial. Ann Surg 2000;231:153-8.
29. Marshall BJ, Valenzuela JE, McCallum RW, et al. Bismuth subsaliculate suppression of Helicobacter pylori in nonulcer dyspepsia: a double blind placebo-controlled trial. Dig Dis Sci 1993;38:1674-80.
30. Bardhan KD, Dallaire C, Eisold H, et al. The treatment of duodenal ulcer with GR 122311X (ranitidine bismuth citrate) and clarithromycin. Gut 1995;37(Suppl. 1):A5.
31. Huo X, Zhang X, Yu C, et al. In oesophageal squamous cells exposed to acidic bile salt medium, omeprazole inhibits IL-8 expression through effects on nuclear factor-êB and activator protein-1. Gut 2014;63:1042-52.
32. Lambert JR, Midolo P. The actions of bismuth in the treatment of Helicobacter pylori infection. Aliment Pharmacol Ther 1997;11:27-33.
33. Namiot DB, Leszczyńska K, Namiot Z, et al. Smoking and drinking habits are important predictors of Helicobacter pylori eradication. Adv Med Sci 2008;53:310-15.
34. Suzuki T, Matsuo K, Ito H, et al. Smoking increases the treatment failure for Helicobacter pylori eradication. Am J Med. 2006;119:217-24.
35. Queiroz DM, Dani R, Silva LD, et al. Factors associated with treatment failure of Helicobacter pylori infection in a developing country. J Clin Gastroenterol. 2002;35:315-20.
36. Perri F, Villani MR, Festa V, et al. Predictors of failure of Helicobacter pylori eradication with the standard 'Maastricht triple therapy'. Aliment Pharmacol Ther. 2001;15:1023-9.
37. Kamada T, Haruma K, Komoto K, et al. Effect of smoking and histological gastritis severity on the rate of H. pylori eradication with omeprazole, amoxicillin, and clarithromycin. Helicobacter 1999;4:204-10.
38. Fock KM, Katelaris P, Sugano K, et al. Second Asia-Pacific Consensus Guidelines for Helicobacter pylori infection. J Gastroenterol Hepatol 2009;24:1587-600.
39. Ma JL, You WC, Gail MH, et al. Helicobacter pylori infection and mode of transmission in a population at high risk of stomach cancer. Int J Epidemiol 1998;27:570-3.
40. Brown LM, Thomas TL, Ma JL, et al. Helicobacter pylori infection in rural China: demographic, lifestyle and environmental factors. Int J Epidemiol 2002;31:638-45.
41. Li ZX, Wang YM, tang FB, et al. NOD1 and NOD2 genetic variants in association with risk of gastric cancer and its precursors in a chinese population. PLoS ONE 2015;10:e0124949.
42. Liu F, Pan K, Zhang X, et al. Genetic variants in cyclooxygenase-2: expression and risk of gastric cancer and its precursors in a Chinese population. Gastroenterology 2006;130:1975-84.
43. Hong SJ, Kim SW. Helicobacter pylori Infection in Gastroesophageal Reflux Disease in the Asian Countries. Gastroenterol Res Pract 2015;2015:985249.
44. Xie T, Cui X, Zheng H, et al. Meta-analysis: eradication of Helicobacter pylori infection is associated with the development of endoscopic gastroesophageal reflux disease. Eur J Gastroenterol Hepatol 2013;25:1195-205.
45. Saad AM, Choudhary A, Bechtold ML. Effect of Helicobacter pylori treatment on gastroesophageal reflux disease (GERD): meta-analysis of randomized controlled trials. Scand J Gastroenterol. 2012;47:129-35.
46. Nam SY, Choi IJ, Ryu KH, et al. Effect of Helicobacter pylori infection and its eradication on reflux esophagitis and reflux symptoms. Am J Gastroenterol. 2010;105:2153-62.
47. Kim N, Lee SW, Kim JI, et al. Effect of Helicobacter pylori Eradication on the Development of Reflux Esophagitis and Gastroesophageal RefluxSymptoms: A Nationwide Multi-Center Prospective Study. Gut Liver 2011;5:437-46.
48. Lü YL, Li Y, Liu GS, et al. Comparison of two gastric cancer screening schemes in a high-risk population. Zhonghua Zhong Liu Za Zhi 2013;35:394-7.